Hemorrhage irrigation reduces need for repeat operations in the most common neurosurgery emergency procedure
According to a study published in The Lancet, irrigation during a craniostomy for a chronic subdural hemorrhage is worthwhile. The randomized comparative trial of five centers is historic in the field of neurosurgery in Finland.

The Finnish study of intraoperative irrigation versus drain alone after evacuation of chronic subdural haematoma (FINISH) investigated whether it is worthwhile to irrigate a chronic subdural hematoma during surgery
Half the patients had their hemorrhage irrigated and half did not. Otherwise, the procedure was carried out in the same way. The main result was that there was significantly less need for repeat procedures in patients who had their hemorrhage irrigated during surgery. Patients’ functional capacity and mortality did not differ between the groups.
The research project involved all Finnish neurosurgery units from the university hospitals of Helsinki, Kuopio, Tampere, Turku, and Oulu. A total of 589 patients with symptomatic chronic subdural hematoma were included in the study.
“Based on the results, we recommend that surgery be performed with irrigation as has been the current treatment protocol in Finland. The role of irrigation in surgery has not been previously studied in a randomized setting and the methods of intervention vary worldwide”, says Co-principal Investigator and Associate Professor Rahul Raj from HUS Neurocenter.
Chronic subdural hematoma requires neurosurgical treatment in the emergency department
Chronic subdural hematoma is the most common condition requiring neurosurgical treatment in the emergency department. Its symptoms may include difficulty walking, loss of strength, speech impediment, memory problems, headaches or epileptic seizures. Without treatment, a hematoma can be fatal. In a trephine craniostomy, a small hole is drilled in the skull and the clot is removed either by irrigating and then inserting a drain or by simply inserting a drain.
Co-principal investigator, Pihla Tommiska, MD, adds that trepanation is one of the most common neurosurgical procedures and the number of operations has increased dramatically in Finland in recent decades.
The study is historic in the field of neurosurgery, as a national randomized comparative study of five centers has never been conducted in Finland before.
The study was designed and implemented in collaboration with the Finnish Centre for Evidence-Based Orthopaedics (FICEBO) research group at the University of Helsinki and HUS. The group is internationally renowned for its randomized comparative studies
”When Rahul Raj, Pihla Tommiska and Kimmo Lönnrot presented their research idea in 2019, it was immediately clear to us that FICEBO would be putting its expertise and resources at the disposal of a great idea and ambitious young researchers. Our hope is that FINISH research can encourage young researchers to do more sustained research work," say Professor Teppo Järvinen and Research Director, Associate Professor Simo Taimela.
The study was published in The Lancet journal on June 6, 2024
Reference:
Raj R*, Tommiska P*, Koivisto T, Leinonen V, Danner N, Posti JP, Laukka D, Luoto TM, Rauhala M, Tetri S, Korhonen TK, Satopää J, Kivisaari R, Luostarinen T, Schwartz C, Czuba T, Taimela S, Lönnrot K*, Järvinen TLN* on behalf of the Finnish study of intraoperative irrigation versus drain alone after evacuation of CSDH (FINISH) study group. Burr-hole drainage with or without irrigation for chronic subdural haematoma (FINISH): a Finnish, nationwide, parallel-group, multicentre, randomised, controlled, non-inferiority trial. The Lancet 2024; 6 June
Link to the publication: https://doi.org/10.1016/S0140-6736(24)00686-X
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
Keywords
Contacts
Rahul Raj, Associate Professor, Specialist in Neurosurgery
Email: rahul.raj@hus.fi
Pihla Tommiska, MD, Specializing Physician
Email: pihla.tommiska@helsinki.fi
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Gips räcker vid frakturer på mediala humerusepikondylen vid armbågsleden hos barn9.9.2025 09:55:56 EEST | Pressmeddelande
I en nyligen publicerad studie framgick det att gipsning som behandling vid frakturer på mediala humerusepikondylen hos barn är en lika effektiv behandlingsform som operation. De resultat som man nu fått stöder gipsbehandling som primär behandlingsform och behandlingen kan förenhetligas på riksnivå.
Kipsi riittää lasten kyynärnivelen koukistajalisäkkeen murtumissa9.9.2025 09:55:56 EEST | Tiedote
Juuri julkaistussa tutkimuksessa selvisi, että lasten kyynärnivelen koukistajalisäkkeen murtumien hoidossa kipsaus on yhtä tehokas hoitomuoto kuin leikkaus. Nyt saadut tulokset tukevat kipsihoidon käyttöä ensisijaisena hoitomuotona, ja hoitoa voidaan yhtenäistää kansallisesti.
Den nyaste ekonomiska prognosen för hela 2025: HUS är på väg att uppnå sina ekonomiska mål för 20258.9.2025 12:09:48 EEST | Pressmeddelande
HUS-sammanslutningens styrelse behandlade på sitt möte verksamheten och ekonomin i januari–juli samt den nyaste årsprognosen för hela 2025. HUS-sammanslutningens operativa resultat beräknas uppvisa ett överskott på 0,1 miljoner euro. Sammanslutningens styrelse fastställde också investeringsplanen och investeringsprogrammet för de kommande åren.
Koko vuoden 2025 uusin talousennuste: HUS pääsemässä vuonna 2025 taloudellisiin tavoitteisiinsa8.9.2025 12:09:48 EEST | Tiedote
HUSin yhtymähallitus käsitteli kokouksessaan tammi–heinäkuun taloutta sekä uusinta koko vuoden 2025 vuosiennustetta. HUS-yhtymän operatiivisen tuloksen ennustetaan päätyvän 0,1 miljoonaa euroa ylijäämäiseksi. Yhtymähallitus vahvisti myös tulevien vuosien investointisuunnitelman ja -ohjelman.
Förebyggande av RS-virusinfektion hos spädbarn inleds på HUS sjukhus3.9.2025 14:17:24 EEST | Pressmeddelande
RS-virus (respiratory syncytial virus, RSV) är den vanligaste orsaken till luftvägsinfektioner som kräver sjukhusvård hos små barn. HUS erbjuder en antikropp som utvecklats mot RS-virus, det vill säga nirsevimab åt nyfödda och barn under ett år som hör till riskgrupperna.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom